Filing Flows › Supernus Pharmaceuticals (SUPN) › Free cash flow
Supernus Pharmaceuticals (SUPN) free cash flow by quarter
Supernus Pharmaceuticals' free cash flow was $6.4M in Q3 2026 (third quarter 2026), -67% from Q4 2025. Over the last 4 quarters it ranged from $6.4M (Q3 2026) to $58.1M (Q2 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.4M | -67% | — |
| Q4 2025 | $19.4M | -67% | — |
| Q2 2025 | $58.1M | +92% | — |
| Q1 2025 | $30.3M | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' free cash flow?
Supernus Pharmaceuticals' free cash flow was $6.4M in Q3 2026 (third quarter 2026), -67% from Q4 2025.
How has Supernus Pharmaceuticals' free cash flow changed?
Over the last 4 quarters it ranged from $6.4M (Q3 2026) to $58.1M (Q2 2025).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →